Completed PHASE2 INTERVENTIONAL 2-arm NCT00587288

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation

Sponsor: Cephalon

Conditions Asthma

Interventions Reslizumab Saline

Updated 8 times since 2017 Last updated: Jul 18, 2016 Started: Apr 30, 2008 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00587288, this PHASE2 trial focuses on Asthma and remains completed. Sponsored by Cephalon, it has been updated 8 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jan 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cephalon
Ception Therapeutics

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Blue Bell, United States , Boston, United States , Calgary, Canada , Centennial, United States , Cincinnati, United States , Colorado Springs, United States , Columbia, United States , Cortland, United States , Denver, United States , Greenfield, United States and 19 more locations